A5009916624- Atrial Fibrillation Management and Outcomes
- Bariatric Surgery and Outcomes
- Venous Thromboembolism Diagnosis and Management
- Cardiac Arrhythmias and Treatments
- Mechanical Circulatory Support Devices
- Transplantation: Methods and Outcomes
- Organ Transplantation Techniques and Outcomes
- Cardiac Structural Anomalies and Repair
- Renal Transplantation Outcomes and Treatments
- Pediatric Urology and Nephrology Studies
- Diet and metabolism studies
- Cardiac electrophysiology and arrhythmias
- Cardiovascular Disease and Adiposity
- Body Contouring and Surgery
- Hematopoietic Stem Cell Transplantation
- Cardiovascular Function and Risk Factors
- Obesity and Health Practices
- Neonatal Health and Biochemistry
- Esophageal and GI Pathology
- Esophageal Cancer Research and Treatment
- Immunotherapy and Immune Responses
- Liver Disease Diagnosis and Treatment
- Cardiac pacing and defibrillation studies
- Nephrotoxicity and Medicinal Plants
- Obstructive Sleep Apnea Research
University of Florida
2016-2023
University of Florida Health
2020-2023
Florida College
2018-2022
Northwestern University
2019
Northwestern Medicine
2018
Boehringer Ingelheim (United States)
2011-2013
McMaster University
2013
Karolinska University Hospital
2013
Thrombosis Research Institute
2013
University College London
2013
Dabigatran is an oral direct thrombin inhibitor that has been shown to be effective alternative warfarin in patients with atrial fibrillation. We evaluated the use of dabigatran mechanical heart valves.In this phase 2 dose-validation study, we studied two populations patients: those who had undergone aortic- or mitral-valve replacement within past 7 days and such at least 3 months earlier. Patients were randomly assigned a 2:1 ratio receive either warfarin. The selection initial dose (150,...
Dabigatran, which is administered in a fixed dose and does not require laboratory monitoring, may be suitable for extended treatment of venous thromboembolism.In two double-blind, randomized trials, we compared dabigatran at 150 mg twice daily with warfarin (active-control study) or placebo (placebo-control patients thromboembolism who had completed least 3 initial months therapy.In the active-control study, recurrent occurred 26 1430 group (1.8%) 18 1426 (1.3%) (hazard ratio dabigatran,...
Dabigatran and warfarin have been compared for the treatment of acute venous thromboembolism (VTE) in a previous trial. We undertook this study to extend those findings.In randomized, double-blind, double-dummy trial 2589 patients with VTE treated low-molecular-weight or unfractionated heparin 5 11 days, we dabigatran 150 mg twice daily warfarin. The primary outcome, recurrent symptomatic, objectively confirmed related deaths during 6 months occurred 30 1279 (2.3%) 28 1289 (2.2%; hazard...
Summary Dabigatran, a specific, reversible direct thrombin inhibitor, is used to prevent ischaemic and haemorrhagic strokes in patients with atrial fibrillation. As every anticoagulant, there need rapidly reverse its effects emergency situations. In an open-label, single-centre phase I study two fixed multiple dosing periods, we investigated the pharmacokinetics, pharmacodynamics safety of dabigatran before, during after 4 hour haemodialysis sessions either 200 or 400 ml/min targeted blood...
Dabigatran, administered orally as the prodrug dabigatran etexilate (DE), is a direct thrombin inhibitor shown to be effective in prevention of stroke and systemic embolism patients with atrial fibrillation (AF). The aim this analysis was derive modeling simulation‐based dose dosing regimen for AF severe renal failure who could potentially benefit from use DE. exposure simulated impairment several combinations doses (75, 110, 150 mg) posologies (BID, QD, Q2D). Simulations were based on...
Older bone marrow transplantation (BMT) recipients are at heightened risk for acute graft-versus-host disease (GVHD) after allogeneic BMT, but the causes of this association poorly understood. Using well-characterized murine BMT models we have explored mechanisms increased GVHD in older mice. mortality, morbidity, and pathologic biochemical indices were all worse old recipients. Donor T cell responses significantly both vivo vitro when stimulated by antigen-presenting cells (APCs) from mice,...
Older bone marrow transplantation (BMT) recipients are at heightened risk for acute graft-versus-host disease (GVHD) after allogeneic BMT, but the causes of this association poorly understood. Using well-characterized murine BMT models we have explored mechanisms increased GVHD in older mice. mortality, morbidity, and pathologic biochemical indices were all worse old recipients. Donor T cell responses significantly both vivo vitro when stimulated by antigen-presenting cells (APCs) from mice,...
Patients receiving long-term anticoagulant treatment with dabigatran may need to undergo a percutaneous coronary intervention (PCI). We studied markers of coagulation activation during elective PCI in patients using order investigate whether upon balloon inflation and stenting is suppressed by without additional heparin treatment.This phase IIa, exploratory, multicentre, randomised, open-label study included 50 stable having an PCI. on standard dual antiplatelet therapy (DAPT) were...
Dabigatran is a new oral anticoagulant recently approved for the prevention of stroke or systemic embolism in patients with atrial fibrillation (AF). Based on its pharmacokinetic profile, dabigatran dosed twice daily. This analysis provides quantitative rationale selection dose regimen this population.The profile was simulated AF given total daily 300 mg, either once Simulations were based population model supplemented data collected from 9522 enrolled pivotal phase III study (RE-LY).The...
Schulman, Sam; Kearon, Clive; Kakkar, Ajay K.; Schellong, Sebastian; Eriksson, Henry; Baanstra, David; Kvamme, Anne Mathilde; Friedman, Jeffrey; Mismetti, Patrick; Goldhaber, Samuel Z. For the RE-MEDY and RE-SONATE Trials Investigators Author Information
We reviewed our experience of morbidly obese patients with end-stage heart failure that underwent left ventricular assist device (LVAD) implantation. From January 1, 2008 to 2018, 240 adult LVADs were implanted at center. the cases presenting and morbid obesity (preoperative body mass index [BMI] ≥ 35 kg/m 2 ) who LVAD-alone, compared a group LVAD bariatric surgery (laparoscopic sleeve gastrectomy [LSG]) as means for weight reduction. Demographic characteristics, perioperative details, BMI,...
To evaluate the pharmacokinetic and pharmacodynamic effects of concomitant administration single loading doses clopidogrel or multiple with dabigatran etexilate.This was an open-label trial in healthy male subjects. In part 1 (pilot, n = 8) 3 (n 12), a dose (300 600 mg, respectively) given concomitantly etexilate at steady state; 2 randomized, multiple-dose, crossover study test treatment being state [300 mg on day 1, then 75 once daily (qd)] dabigatran.Bioavailability moderately increased...
Summary Dabigatran was as effective warfarin for the acute treatment of venous thromboembolism in RE-COVER and II trials. We compared incidence bleeding with dabigatran versus pooled data from these studies. The localisation, severity, impact key factors on bleeding, were between group. Altogether, 2553 patients received 2554 warfarin, each a mean 164 days. any event significantly lower (hazard ratio [HR] 0.70; 95 % confidence interval [CI], 0.61–0.79), composite MBEs clinically relevant...
Children with developmental trauma are at risk for severe and complex behavioral problems, often requiring long-term residential day treatment. The Neurosequential Model of Therapeutics (NMT) is a developmentally sensitive approach to clinical work capacity-building component focusing on attachment, the impact maltreatment trauma, emerging concepts in psychology, neuroscience traumatology. Research has demonstrated its effectiveness trauma-exposed populations. NMT training may help providers...